EPS for Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Expected At $-0.89

May 17, 2018 - By Robert Sims

Analysts expect Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) to report $-0.89 EPS on June, 15.They anticipate $0.85 EPS change or 48.85 % from last quarter’s $-1.74 EPS. After having $-0.75 EPS previously, Biohaven Pharmaceutical Holding Company Ltd.’s analysts see 18.67 % EPS growth. The stock increased 0.60% or $0.18 during the last trading session, reaching $29.95. About 453,190 shares traded. Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) has 0.00% since May 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. The company has market cap of $1.16 billion. The Company’s advanced product candidate includes rimegepant, which is intended to initiate two Phase III clinical trials for the acute treatment of migraine; and trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia. It currently has negative earnings. The firm also develops BHV-3500 for the prevention of chronic and episodic migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities.

More notable recent Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) news were published by: Prnewswire.com which released: “Biohaven Pharmaceuticals Reports First Quarter 2018 Financial and Recent Business Results” on May 15, 2018, also Seekingalpha.com with their article: “Biohaven Pharma announces key milestones for 2018” published on May 15, 2018, Seekingalpha.com published: “Your Daily Pharma Scoop: Biohaven Updates, MEIP Offering, Kite European Expansions” on May 17, 2018. More interesting news about Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) were released by: Prnewswire.com and their article: “Biohaven Initiates Expanded Access Program for Sublingual BHV-0223 ZYDIS® Orally Dissolving Tablets for Patients …” published on May 09, 2018 as well as Seekingalpha.com‘s news article titled: “Biohaven announces secondary endpoint results from Phase 3 clinical trials BHV3000-301 and 302 of Rimegepant” with publication date: April 23, 2018.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: